Treatment for CML has changed dramatically over the past few decades. Not long ago, options were limited to chemotherapy and interferon, treatments that often controlled the disease only briefly and with significant side effects. The arrival of targeted pills called tyrosine kinase inhibitors (TKIs) like imatinib transformed CML into a highly treatable condition. Many people now live long lives with the disease well controlled on daily oral therapy.
At the 2026 ASCO meeting, new long-term data from the ASC4FIRST study suggested that a newer medication, asciminib, may represent another step forward in how CML is treated. Asciminib works differently from TKI drugs. Instead of broadly blocking the cancer signal, it targets a specific part of the abnormal protein that drives CML. This more precise approach may allow it to be both effective and better tolerated. The trial followed patients with newly diagnosed CML who were randomly assigned to receive either asciminib or another standard TKIs chosen by their doctor. After nearly three years of follow-up, the results showed that patients taking asciminib were more likely to achieve deep and early responses, meaning the leukemia was reduced to extremely low or even undetectable levels in the blood.
Read MoreWhile these results are encouraging, some questions remain. Although deeper responses are a positive sign, it is not yet proven that this means more patients will be able to safely stop treatment earlier or more often. Long-term follow-up is still needed to understand whether these improvements translate into higher rates of treatment-free remission, where patients can remain in remission without taking daily medication.
Even so, the progress is meaningful. CML has already gone from a life-threatening illness to a chronic, manageable condition for many patients. Asciminib may move the field one step closer to the next goal of long-term control possibly with the ability to live without ongoing therapy.
As Dr. Cortes reflected on how far the field has come, he said, “When we started the era of these targeted drugs 25 years ago, we thought patients would need to stay on treatment for life. Now our challenge is figuring out how to help more patients safely stop treatment and remain in remission.” For patients, that shift represents something profound not just living longer with CML, but living well beyond treatment.
Learn more about SurvivorNet's rigorous medical review process.
